进展期肉瘤患者阿帕替尼抗血管治疗对生活质量的影响  

Effect on quality of life of advanced sarcoma patients after anti-angiogenesis therapies of apatinib

作　　者：杨晨晨 董森[1] 许婕[1] 谢璐[1] 杨毅[1] 姬涛[1] 郭卫[1] 汤小东[1] YANG Chen-chen;DONG Sen;XU Jie;XIE Lu;YANG Yi;JI Tao;GUO Wei;TANG Xiao-dong(Musculoskeletal Tumor Center,Peking University People’s Hospital,Beijing,100044,China)

机构地区：[1]北京大学人民医院骨肿瘤科,100044

出　　处：《中国骨与关节杂志》2024年第5期365-371,共7页Chinese Journal of Bone and Joint

摘　　要：目的分析两项阿帕替尼治疗进展期肉瘤患者的临床试验(NCT0271100和NCT03491371)中患者的生活质量(quality of life,QoL)和不良事件(adverse effects,AEs)。方法利用t检验对患者的动态QoL进行评估,采用线性回归模型分析AEs对总体健康状况(general health score,GHS)的影响,并找出影响QoL最重要的因素。结果虽然GHS在患者接受阿帕替尼治疗后有轻微下降的趋势,但差异无统计学意义(P=0.154)。最常见的3或4级AEs为:气胸(14.6%)、伤口开裂(11.0%)、食欲不振(6.1%)和高血压(6.1%)。气胸的发生与GHS的降低具有高度相关性(P=0.002)。结论进展期肉瘤患者的QoL在接受阿帕替尼治疗后没有显著的下降。气胸是最常见的3或4级AEs,也是总QoL下降的最主要影响因素,造成了患者功能评分的下降和症状评分的增加。Objective We analyzed files about quality of life(QoL)and adverse effects(AEs)from two clinical trials of apatinib for advanced sarcoma(NCT02711007 and NCT03491371).Methods Dynamic QoL scores in three major domains were analyzed by t-test.The effect of these ese AEs on general health score(GHS)was then analyzed using linear regression models to find out which was the most important factor affecting QoL.Results QoL has a slight end of decline after anti-angiogenic therapy,however,with no statistical significance(P=0.154).Pneumothorax(14.6%),wound dehiscence(11.0%),appetite loss(6.1%)and hypertension(6.1%)were the most common grade 3/4 AEs.The appearance of pneumothorax was closely related to a lower GHS(P=0.002).Conclusions QoL for advanced sarcoma patients has a non-significant trend of decline after anti-angiogenic therapy.Pneumothorax,as the most common grade 3/4 AEs,is the major concern related to poor general quality of life,resulting in poor function and aggravated symptoms.

关 键 词：血管生成抑制剂 肉瘤 药物相关性副作用和不良反应 生活质量 阿帕替尼 

分 类 号：R738.1[医药卫生—肿瘤]